细胞外囊泡与口腔肿瘤免疫

doi:10.13591/j.cnki.kqyx.2023.09.001

Abstract

Abstract:

Extracellular vesicles are nanoscale membranous vesicles secreted by cells and are an important mediator for intercellular communication. Tumor-derived extracellular vesicles not only affect tumorigenesis and progression, but also mediate tumor immune escape and therapeutic resistance through interaction with immune cells. Liquid biopsies based on extracellular vesicles and therapeutic strategies targeting extracellular vesicles have promising applications in tumor therapy. This paper describes the biological properties of extracellular vesicles and their role in immune regulation of oral tumors, and discusses therapeutic strategies for oral tumors based on extracellular vesicles, providing a theoretical basis for promoting the clinical translation of extracellular vesicles.

Key words: extracellular vesicle, oral tumor, immune cell, biomarker, immunotherapy

CLC Number:

R739.8

XIAO Bolin, ZHANG Wei, CHEN Gang. Extracellular vesicles and oral tumor immunity[J]. Stomatology, 2023, 43(9): 769-774.

Figures/Tables 2

References 41

[1]	Muzio LL, Ballini A, Cantore S, et al. Overview of Candida albicans and human papillomavirus (HPV) infection agents and their biomolecular mechanisms in promoting oral cancer in pediatric patients[J]. Biomed Res Int, 2021, 2021: 7312611.
[2]	Morad G, Helmink BA, Sharma P, et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade[J]. Cell, 2022, 185(3):576. doi: 10.1016/j.cell.2022.01.008 pmid: 35120665
[3]	Ferris RL, Licitra L. PD-1 immunotherapy for recurrent or metastatic HNSCC[J]. Lancet, 2019, 394(10212):1882-1884. doi: S0140-6736(19)32539-5 pmid: 31679948
[4]	Kalluri R, McAndrews KM. The role of extracellular vesicles in cancer[J]. Cell, 2023, 186(8):1610-1626. doi: 10.1016/j.cell.2023.03.010 pmid: 37059067
[5]	Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response[J]. Nature, 2018, 560(7718):382-386. doi: 10.1038/s41586-018-0392-8
[6]	van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles[J]. Nat Rev Mol Cell Biol, 2018, 19(4):213-228. doi: 10.1038/nrm.2017.125
[7]	Raposo G, Stoorvogel W. Extracellular vesicles: Exosomes, microvesicles, and friends[J]. J Cell Biol, 2013, 200(4):373-383. doi: 10.1083/jcb.201211138 pmid: 23420871
[8]	Henne WM, Buchkovich NJ, Emr SD. The ESCRT pathway[J]. Dev Cell, 2011, 21(1):77-91. doi: 10.1016/j.devcel.2011.05.015 pmid: 21763610
[9]	Stenmark H. Rab GTPases as coordinators of vesicle traffic[J]. Nat Rev Mol Cell Biol, 2009, 10(8):513-525. doi: 10.1038/nrm2728
[10]	Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018):A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines[J]. J Extracell Vesicles, 2018, 7(1):1535750. doi: 10.1080/20013078.2018.1535750
[11]	Dżaman K, Czerwaty K. Extracellular vesicle-based drug delivery systems for head and neck squamous cell carcinoma: A systematic review[J]. Pharmaceutics, 2023, 15(5):1327. doi: 10.3390/pharmaceutics15051327
[12]	Ludwig S, Sharma P, Theodoraki MN, et al. Molecular and functional profiles of exosomes from HPV(+) and HPV (-) head and neck cancer cell lines[J]. Front Oncol, 2018, 8: 445. doi: 10.3389/fonc.2018.00445 pmid: 30370252
[13]	Muller L, Mitsuhashi M, Simms P, et al. Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets[J]. Sci Rep, 2016, 6: 20254. doi: 10.1038/srep20254 pmid: 26842680
[14]	Theodoraki MN, Yerneni SS, Hoffmann TK, et al. Clinical significance of PD-L1⁺ exosomes in plasma of head and neck cancer patients[J]. Clin Cancer Res, 2018, 24(4):896-905. doi: 10.1158/1078-0432.CCR-17-2664
[15]	Hadavand M, Hasni S. Exosomal biomarkers in oral diseases[J]. Oral Dis, 2019, 25(1):10-15. doi: 10.1111/odi.12878 pmid: 29688608
[16]	Maybruck BT, Pfannenstiel LW, Diaz-Montero M, et al. Tumor-derived exosomes induce CD8⁺ T cell suppressors[J]. J Immunother Cancer, 2017, 5(1):65. doi: 10.1186/s40425-017-0269-7 pmid: 28806909
[17]	Xiao BL, Wang XL, Xia HF, et al. HRS regulates small extracellular vesicle PD-L1 secretion and is associated with anti-PD-1 treatment efficacy[J]. Cancer Immunol Res, 2023, 11(2):228-240. doi: 10.1158/2326-6066.CIR-22-0277
[18]	Bellmunt ÀM, López-Puerto L, Lorente J, et al. Involvement of extracellular vesicles in the macrophage-tumor cell communication in head and neck squamous cell carcinoma[J]. PLoS One, 2019, 14(11):e0224710. doi: 10.1371/journal.pone.0224710
[19]	Xiao M, Zhang JJ, Chen WJ, et al. M1-like tumor-associated macrophages activated by exosome-transferred THBS1 promote malignant migration in oral squamous cell carcinoma[J]. J Exp Clin Cancer Res, 2018, 37(1):143. doi: 10.1186/s13046-018-0815-2 pmid: 29986759
[20]	Tong FJ, Mao XH, Zhang SW, et al. HPV⁺ HNSCC-derived exosomal miR-9 induces macrophage M1 polarization and increases tumor radiosensitivity[J]. Cancer Lett, 2020, 478: 34-44. doi: 10.1016/j.canlet.2020.02.037
[21]	Wang YN, Qin X, Zhu XQ, et al. Oral cancer-derived exosomal NAP1 enhances cytotoxicity of natural killer cells via the IRF-3 pathway[J]. Oral Oncol, 2018, 76:34-41. doi: 10.1016/j.oraloncology.2017.11.024
[22]	Ludwig S, Floros T, Theodoraki MN, et al. Suppression of lymphocyte functions by plasma exosomes correlates with disease activity in patients with head and neck cancer[J]. Clin Cancer Res, 2017, 23(16):4843-4854. doi: 10.1158/1078-0432.CCR-16-2819 pmid: 28400428
[23]	Asadirad A, Hashemi SM, Baghaei K, et al. Phenotypical and functional evaluation of dendritic cells after exosomal delivery of miRNA-155[J]. Life Sci, 2019, 219:152-162. doi: S0024-3205(19)30005-0 pmid: 30625290
[24]	Zhao ZJ, Zhang HY, Zeng Q, et al. Exosomes from 5-aminolevulinic acid photodynamic therapy-treated squamous carcinoma cells promote dendritic cell maturation[J]. Photodiagnosis Photodyn Ther, 2020, 30: 101746. doi: 10.1016/j.pdpdt.2020.101746
[25]	Li L, Cao BR, Liang XH, et al. Microenvironmental oxygen pressure orchestrates an anti- and pro-tumoral γδ T cell equilibrium via tumor-derived exosomes[J]. Oncogene, 2019, 38(15):2830-2843. doi: 10.1038/s41388-018-0627-z
[26]	Schroeder JC, Puntigam L, Hofmann L, et al. Circulating exosomes inhibit B cell proliferation and activity[J]. Cancers(Basel), 2020, 12(8):2110.
[27]	Hoshino A, Kim HS, Bojmar L, et al. Extracellular vesicle and particle biomarkers define multiple human cancers[J]. Cell, 2020, 182(4):1044-1061.e18. doi: S0092-8674(20)30874-6 pmid: 32795414
[28]	Theodoraki MN, Hoffmann TK, Whiteside TL. Separation of plasma-derived exosomes into CD3⁽⁺⁾ and CD3^(-)fractions allows for association of immune cell and tumour cell markers with disease activity in HNSCC patients[J]. Clin Exp Immunol, 2018, 192(3):271-283. doi: 10.1111/cei.13113 pmid: 29431869
[29]	Li Y, Chen ZK, Duan X, et al. Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer[J]. Exp Mol Med, 2022, 54(9):1379-1389. doi: 10.1038/s12276-022-00856-3 pmid: 36117219
[30]	Liu T, Chen G, Sun DW, et al. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma[J]. Acta Biochim Biophys Sin, 2017, 49(9):808-816. doi: 10.1093/abbs/gmx078
[31]	Li RW, Zhou YF, Zhang MM, et al. Oral squamous cell carcinoma-derived EVs promote tumor progression by regulating inflammatory cytokines and the IL-17A-induced signaling pathway[J]. Int Immunopharmacol, 2023, 118: 110094. doi: 10.1016/j.intimp.2023.110094
[32]	Orme JJ, Enninga EAL, Lucien-Matteoni F, et al. Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles[J]. J Immunother Cancer, 2020, 8(2):e001113. doi: 10.1136/jitc-2020-001113
[33]	Shin S, Ko H, Kim CH, et al. Curvature-sensing peptide inhibits tumour-derived exosomes for enhanced cancer immunotherapy[J]. Nat Mater, 2023, 22(5):656-665. doi: 10.1038/s41563-023-01515-2 pmid: 36959501
[34]	Wu PP, Zhang B, Ocansey DKW, et al. Extracellular vesicles: A bright star of nanomedicine[J]. Biomaterials, 2021, 269: 120467. doi: 10.1016/j.biomaterials.2020.120467
[35]	Yang TZ, Martin P, Fogarty B, et al. Exosome delivered antican-cer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio[J]. Pharm Res, 2015, 32(6):2003-2014. doi: 10.1007/s11095-014-1593-y
[36]	Wang CH, Chen L, Huang YY, et al. Exosome-delivered TRPP2 siRNA inhibits the epithelial-mesenchymal transition of FaDu cells[J]. Oncol Lett, 2019, 17(2):1953-1961. doi: 10.3892/ol.2018.9752 pmid: 30675260
[37]	Kase Y, Uzawa K, Wagai S, et al. Engineered exosomes deliver-ing specific tumor-suppressive RNAi attenuate oral cancer progression[J]. Sci Rep, 2021, 11(1):5897. doi: 10.1038/s41598-021-85242-1
[38]	Wu M, Chen ZK, Xie QH, et al. One-step quantification of salivary exosomes based on combined aptamer recognition and quantum dot signal amplification[J]. Biosens Bioelectron, 2021, 171: 112733. doi: 10.1016/j.bios.2020.112733
[39]	Dong HY, Xie QH, Pang DW, et al. Precise selection of aptamers targeting PD-L1 positive small extracellular vesicles on magnetic chips[J]. Chem Commun(Camb), 2021, 57(29):3555-3558.
[40]	Xu R, Yu ZL, Liu XC, et al. Aptamer-assisted traceless isolation of PD-L1-positive small extracellular vesicles for dissecting their subpopulation signature and function[J]. Anal Chem, 2023, 95(2):1016-1026.
[41]	Yu ZL, Liu XC, Wu M, et al. Untouched isolation enables targe-ted functional analysis of tumour-cell-derived extracellular vesicles from tumour tissues[J]. J Extracell Vesicles, 2022, 11(4):e12214. doi: 10.1002/jev2.v11.4

Extracellular vesicles and oral tumor immunity

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 41

Related Articles 11

Recommended Articles

Metrics

Comments

[1]	Dilibaier·YIMINGJIANG , Duolikun·WUFUER . Recent research progress of pathogenic gene and diagnosis of non-syndromic cleft lip and palate [J]. Stomatology, 2023, 43(8): 757-762.
[2]	SUN Yuezhang,WANG Qi. Morphological and immune characteristics of periodontal tissues under hyperglycemia [J]. Stomatology, 2023, 43(2): 153-158.
[3]	XU Yingjiao, WANG Shan. Research progress on the role of salivary exosomes in oral squamous cell carcinoma [J]. Stomatology, 2022, 42(7): 664-667.
[4]	HOU Yiming, LI Na, YU Wenqian, CHEN Lei. Research progress of histone modification in oral squamous cell carcinoma [J]. Stomatology, 2022, 42(7): 650-654.
[5]	SHA Sha, LU Lingbo, GUO Peipei, CHEN Shu, JIN Muhan, XU Rongyao. Clinical study on correlation between miRNA-143/145 in saliva and estrogen-deficient osteoporosis [J]. Stomatology, 2022, 42(6): 515-520.
[6]	ZHAO Yuqi, TIAN Shenglan, LI Ying, WANG Aiqin. Research progress of activated matrix metalloproteinase-8 as a periodontal biomarker [J]. Stomatology, 2022, 42(4): 373-376.
[7]	. Exosomes regulate the occurrence and development of oral squamous cell carcinoma [J]. , 2021, 41(11): 1034-1038.
[8]	. Screening of related genetic markers for oral squamous cell carcinoma prognosis [J]. , 2019, 39(8): 679-684.
[9]	hao ming zhao huaqiang zhao. Application potential exploration of B7H5 used as drug combination target in the immunotherapy of oromaxillofacial head and neck tumor [J]. , 2018, 38(11): 1048-1052.
[10]	Yu XueDi. Application of metabolomics in study on biomarkers for oral carcinoma and oral precancerous lesions [J]. , 2017, 37(4): 369-372.
[11]	. Saliva markers for periodontitis and their potential applications [J]. , 2017, 37(11): 961-964.